Lital Magid

About Lital Magid

I am a senior pharmaceutical executive and scientific strategist with over a decade of progressive leadership in drug development, specializing in DMPK, Translational Biomarkers, and early-phase clinical strategy. Throughout my career, I have consistently advanced innovation at the interface of discovery and clinical entry, leading complex global programs and shaping regulatory, scientific, and operational frameworks that drive high-impact outcomes.Currently serving as Director of DMPK at Teva Pharmaceuticals, I lead five development programs spanning biologics, biosimilars, and small molecules in CNS and immunology. My role integrates end-to-end project leadership, scientific oversight, and cross-functional collaboration—ensuring the successful translation of discovery-phase assets into clinical-stage therapies. I provide strategic direction across biomarker integration, PBPK Modeling, eCTD Submissions, and dose selection strategy, anchoring every step in data-driven regulatory and translational decisions.My expertise spans key disciplines including Biomarker Discovery, Pharmacokinetics, Pharmacodynamics, and Regulatory Submissions. I bring a proven ability to manage global cross-functional teams, orchestrate nonclinical and IND-enabling studies, and coordinate between internal stakeholders and CRO partners to maintain scientific integrity, efficiency, and regulatory readiness. In addition, I actively contribute to licensing and acquisition efforts, conducting scientific Due Diligence and Risk-Benefit Assessments to inform business-critical decisions.A key pillar of my leadership lies in Innovation Strategy—driving Drug Repurposing initiatives and molecular innovation across multiple therapeutic areas. My background includes translational research in synthetic cannabinoids targeting CB2 receptors, resulting in a patented compound later acquired by Roche and Bioline. I was honored with multiple awards for scientific innovation and commercialization, including the Kaye Innovation Award.With a Ph.D. in Medicinal Chemistry and broad academic, clinical, and regulatory training, I bring both scientific depth and strategic vision to every project I lead. Whether mentoring senior scientists or steering early development programs through global regulatory milestones, I am committed to enabling smarter, faster, and more precise drug development that ultimately enhances patient lives.

Experience

1. Director, Dmpk Team and Project Leader

   Teva Pharmaceuticals

   Jan 2023 — Present · US

   In my current role I lead and oversee the scientific and strategic direction of five development programs progressing from early discovery to clinical entry. These programs span biologics, biosimilars, and small molecules across therapeutic areas including CNS and immunology, requiring tailored translational strategies and complex cross-functional coordination.I guide multidisciplinary teams through data-driven decision-making, ensuring that biomarker integration, PBPK Modeling, and regulatory deliverables are aligned with program goals and health authority expectations. A core part of my leadership involves steering preclinical regulatory submissions, including IND packages and eCTD dossiers, and leveraging predictive models to inform dose selection and clinical trial design.In addition to scientific leadership, I serve as a mentor to senior-level scientists and DMPK leaders, supporting professional growth while promoting operational excellence and scientific rigor. I regularly interface with external CRO partners to manage outsourced activities, maintain quality standards, and ensure timely execution across global timelines.Beyond development execution, I play a critical role in licensing and acquisition initiatives by conducting due diligence, evaluating scientific risk-benefit profiles, and advising on the strategic fit of assets under consideration. I collaborate closely with regulatory, clinical, and business development counterparts to shape a cohesive vision for translational innovation that accelerates pipeline progress and enables smarter, more targeted therapies.

Education

• The Hebrew University of Jerusalem

  MSc, Medicinal Chemistry

  2004 — 2006

• Tel Aviv University

  Registered Nursing/Registered Nurse

• The Hebrew University of Jerusalem

  PhD, Medicinal Chemistry

  2006 — 2012

Skills

• Hplc
• Molecular Biology
• Cell Biology
• In Vivo
• Biotechnology
• Animal Models
• Biochemistry
• Microbiology
• Western Blotting
• Drug Delivery
• Lifesciences